Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer.

PubWeight™: 1.20‹?› | Rank: Top 10%

🔗 View Article (PMC 2409536)

Published in Br J Cancer on June 14, 2004

Authors

M Di Maio, C Gridelli, C Gallo, L Manzione, L Brancaccio, S Barbera, S F Robbiati, G P Ianniello, F Ferraù, E Piazza, L Frontini, F Rosetti, F Carrozza, A Bearz, M Spatafora, V Adamo, L Isa, R V Iaffaioli, E Di Salvo, F Perrone

Articles citing this

Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol (2008) 4.70

Distress screening in a multidisciplinary lung cancer clinic: prevalence and predictors of clinically significant distress. Lung Cancer (2006) 1.67

Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer (2009) 1.37

Pain in hospitalized children: a prospective cross-sectional survey of pain prevalence, intensity, assessment and management in a Canadian pediatric teaching hospital. Pain Res Manag (2008) 1.30

The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer (2006) 1.08

Bone matters in lung cancer. Ann Oncol (2012) 1.08

Biologic mechanisms of oral cancer pain and implications for clinical therapy. J Dent Res (2011) 1.01

Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer (2009) 1.01

The Supportive Care Task Force at the University of L'Aquila: 2-years experience. Support Care Cancer (2005) 0.92

Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis. Med Sci Monit (2015) 0.87

Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey. Support Care Cancer (2008) 0.86

Reducing the burden of bone metastases: current concepts and treatment options. Support Care Cancer (2013) 0.86

Quality of life in cancer patients with pain in beijing. Chin J Cancer Res (2012) 0.85

Demethylating drugs as novel analgesics for cancer pain. Clin Cancer Res (2014) 0.84

CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol (2014) 0.84

Prescription patterns of analgesics in the last 3 months of life: a retrospective analysis of 10202 lung cancer patients. Br J Cancer (2011) 0.82

Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit. Support Care Cancer (2013) 0.80

Factors associated with pain among ambulatory patients with cancer with advanced disease at a comprehensive cancer center. J Oncol Pract (2012) 0.79

The Characteristics and the Pharmacological Management of Cancer Pain and Its Effect on the Patients' Daily Activities and their Quality of Life: A Cross - Sectional study from Malaysia. J Clin Diagn Res (2013) 0.78

Collaboration between physicians and a hospital-based palliative care team in a general acute-care hospital in Japan. BMC Palliat Care (2010) 0.78

The Prevalence and Characteristics of Pain in Critically Ill Cancer Patients: A Prospective Nonrandomized Observational Study. Indian J Palliat Care (2015) 0.77

Integrating palliative care with intensive care for critically ill patients with lung cancer. Ann Intensive Care (2012) 0.77

Cancer pain management in an oncological ward in a comprehensive cancer center with an established palliative care unit. Support Care Cancer (2013) 0.77

Rationale, design, and implementation protocol of the Dutch clinical practice guideline pain in patients with cancer: a cluster randomised controlled trial with Short Message Service (SMS) and Interactive Voice Response (IVR). Implement Sci (2011) 0.76

Pain experiences among a population-based cohort of current, former, and never regular smokers with lung and colorectal cancer. Cancer (2014) 0.75

Agreement between personally generated areas of quality of life concern and standard outcome measures in people with advanced cancer. Support Care Cancer (2016) 0.75

Articles cited by this

Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99

Global cancer statistics in the year 2000. Lancet Oncol (2001) 11.11

Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89

Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54

Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA (1998) 6.88

Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol (2004) 5.84

Skeletal complications of malignancy. Cancer (1997) 5.41

Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA (2002) 5.30

Measurement of the quality of life in cancer survivors. Qual Life Res (1995) 3.51

Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med (1997) 3.48

The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer (1994) 3.45

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41

Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med (1993) 3.25

Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst (1999) 3.24

Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain (1995) 2.69

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol (1996) 2.50

A validation study of the WHO method for cancer pain relief. Cancer (1987) 2.32

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2003) 2.09

The prevalence and severity of pain in cancer. Cancer (1982) 2.07

Opioid prescription in Italy: new law, no effect. Lancet (2002) 2.01

Multicentre study of cancer pain and its treatment in France. BMJ (1995) 1.78

Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain (1997) 1.75

New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med (1994) 1.70

Severe undertreatment of cancer pain: a 3-year survey of the German situation. J Pain Symptom Manage (1995) 1.32

The prevalence of pain in four cancers. Cancer (1987) 1.25

Prevalence and management of cancer pain in South Africa. Pain (2001) 1.17

Undertreatment of cancer pain in elderly patients. JAMA (1998) 1.09

Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04

The effects of pain severity on health-related quality of life: a study of Chinese cancer patients. Cancer (1999) 1.03

Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst (2002) 0.94

Cancer pain management. Cancer Control (2000) 0.88

Multicenter study of pain and its management in patients with advanced cancer in Korea. J Pain Symptom Manage (2003) 0.87

Articles by these authors

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75

Mental health research priorities in low- and middle-income countries of Africa, Asia, Latin America and the Caribbean. Br J Psychiatry (2009) 3.11

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 3.06

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab (2000) 2.43

Effects of insufficient sleep on blood pressure in hypertensive patients: a 24-h study. Am J Hypertens (1999) 2.13

Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology (1995) 2.12

Informed versus randomised consent to clinical trials. Lancet (1995) 2.07

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05

Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol (1997) 1.94

Gastrointestinal symptoms in patients with asthma. Arch Dis Child (2000) 1.82

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol (1996) 1.74

A study of the pathology of the crush syndrome. Surg Gynecol Obstet (1982) 1.73

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol (2011) 1.73

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol (2000) 1.69

Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol (2009) 1.67

Diagnosis of cysticercosis in endemic regions. The Cysticercosis Working Group in Peru. Lancet (1991) 1.63

Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut (2001) 1.61

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer (1998) 1.55

Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol (2005) 1.54

Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (1999) 1.54

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54

Immunodiagnosis of human cysticercosis (Taenia solium): a field comparison of an antibody-enzyme-linked immunosorbent assay (ELISA), an antigen-ELISA, and an enzyme-linked immunoelectrotransfer blot (EITB) assay in Peru. The Cysticercosis Working Group in Peru (CWG). Am J Trop Med Hyg (1992) 1.53

Constitutive RNA synthesis for the yeast activator ADR1 and identification of the ADR1-5c mutation: implications in posttranslational control of ADR1. Mol Cell Biol (1986) 1.49

Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer (1995) 1.42

Computerized tomography of the abdomen and pelvis with peritoneal administration of soluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer. Gynecol Oncol (1994) 1.42

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res (2010) 1.40

Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days. Lung Cancer (2005) 1.39

[Rubella in pregnancy. Management and prevention]. Presse Med (1999) 1.39

Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer (1995) 1.35

Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers (2004) 1.35

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol (2008) 1.31

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol (2007) 1.28

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol (1999) 1.27

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer (2004) 1.26

Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest (2001) 1.26

Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? Eur J Cancer (1996) 1.26

The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer (1995) 1.25

Lung cancer in the elderly. Eur J Cancer (1997) 1.19

Intestinal side-effects of docetaxel/vinorelbine combination. Lancet (2000) 1.19

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17

The role of Aurora-A inhibitors in cancer therapy. Ann Oncol (2007) 1.16

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol (1994) 1.15

A randomized clinical trial comparing 22G and 25G needles in endoscopic ultrasound-guided fine-needle aspiration of solid lesions. Endoscopy (2011) 1.15

Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol (2009) 1.14

Interleukin-8 induces lymphocyte chemotaxis into the pleural space. Role of pleural macrophages. Am J Respir Crit Care Med (1999) 1.14

Long-term sonographic follow-up of rheumatoid and psoriatic proliferative knee joint synovitis. Br J Rheumatol (1996) 1.13

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. Lung Cancer (2011) 1.13

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer (2011) 1.12

EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol (2009) 1.12

Questionnaires, spirometry and PEF monitoring in epidemiological studies on elderly respiratory patients. Eur Respir J Suppl (2003) 1.11

Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol (2010) 1.10

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer (2006) 1.09

Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol (2007) 1.08

Clinical experiences with antimonyl-dimethylcysteino-tartrate (NAP) in a rural population infected with Schistosoma mansoni. Ann Trop Med Parasitol (1970) 1.07

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol (2003) 1.06

Analysis of ferritins in lymphoblastoid cell lines and in the lens of subjects with hereditary hyperferritinemia-cataract syndrome. Blood (1998) 1.04

Dasatinib: a new step in molecular target therapy. Ann Oncol (2007) 1.04

Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04

First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol (2006) 1.03

Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. Oncology (2000) 1.02

Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol (2011) 1.02

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol (1988) 1.01

Child survivors of suicide: psychosocial characteristics. J Am Acad Child Adolesc Psychiatry (1997) 1.00

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol (2000) 1.00

Posture and movement in healthy preterm infants in supine position in and outside the nest. Arch Dis Child Fetal Neonatal Ed (2007) 0.99

Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology (1995) 0.99

Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer (2009) 0.99

Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas. Anticancer Res (2011) 0.98

Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol (1982) 0.98

Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis (1993) 0.97

Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol (2005) 0.97

Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. Lancet (1988) 0.97

The impact of a psychological intervention on quality of life in non-metastatic breast cancer. Eur J Cancer (1996) 0.96